250 related articles for article (PubMed ID: 37658376)
21. Hyperoside Inhibits RNF8-mediated Nuclear Translocation of β-catenin to Repress PD-L1 Expression and Prostate Cancer.
Chen J; Zhao Y; Wang X; Zang L; Yin D; Tan S
Anticancer Agents Med Chem; 2024; 24(6):464-476. PubMed ID: 38305391
[TBL] [Abstract][Full Text] [Related]
22. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
23. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
24. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma.
Qu T; Zhang W; Yan C; Ren D; Wang Y; Guo Y; Guo Q; Wang J; Liu L; Han L; Li L; Huang Q; Cao L; Ye Z; Zhang B; Zhao Q; Cao W
J Transl Med; 2023 May; 21(1):341. PubMed ID: 37217923
[TBL] [Abstract][Full Text] [Related]
25. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
[TBL] [Abstract][Full Text] [Related]
26. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
27. New steps in the Wnt/beta-catenin signal transduction pathway.
Sakanaka C; Sun TQ; Williams LT
Recent Prog Horm Res; 2000; 55():225-36. PubMed ID: 11036939
[TBL] [Abstract][Full Text] [Related]
28. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma.
Yang RH; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Fang D; Xie SQ
Biochem Pharmacol; 2023 Feb; 208():115378. PubMed ID: 36513141
[TBL] [Abstract][Full Text] [Related]
29. WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses.
Mortezaee K
Clin Exp Med; 2024 Jan; 24(1):15. PubMed ID: 38280119
[TBL] [Abstract][Full Text] [Related]
30. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.
Malgundkar SH; Burney I; Al Moundhri M; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
BMC Cancer; 2020 May; 20(1):374. PubMed ID: 32366234
[TBL] [Abstract][Full Text] [Related]
31. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
[TBL] [Abstract][Full Text] [Related]
32. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
[TBL] [Abstract][Full Text] [Related]
33. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer.
Ma Y; Marinkova R; Nenkov M; Jin L; Huber O; Sonnemann J; Peca N; Gaßler N; Chen Y
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232331
[TBL] [Abstract][Full Text] [Related]
35. KCTD1 suppresses canonical Wnt signaling pathway by enhancing β-catenin degradation.
Li X; Chen C; Wang F; Huang W; Liang Z; Xiao Y; Wei K; Wan Z; Hu X; Xiang S; Ding X; Zhang J
PLoS One; 2014; 9(4):e94343. PubMed ID: 24736394
[TBL] [Abstract][Full Text] [Related]
36. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Jiang Y; Yuan Y; Chen M; Li S; Bai J; Zhang Y; Sun Y; Wang G; Xu H; Wang Z; Zheng Y; Nie H
Theranostics; 2021; 11(18):9162-9176. PubMed ID: 34522232
[No Abstract] [Full Text] [Related]
37. DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β.
Liu XF; Li XY; Zheng PS; Yang WT
Cell Death Dis; 2018 Mar; 9(3):339. PubMed ID: 29497051
[TBL] [Abstract][Full Text] [Related]
38. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
39. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
40. FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling.
Cai J; Feng D; Hu L; Chen H; Yang G; Cai Q; Gao C; Wei D
Br J Cancer; 2015 Dec; 113(12):1720-9. PubMed ID: 26633557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
